GSK announced positive results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first-line advanced ovarian cancer. The trial met its primary endpoint, demonstrating statistically significant progression-free survival (PFS) improvement with dostarlimab added to standard chemotherapy and niraparib maintenance, with or without bevacizumab.The key secondary endpoint of overall survival did not reach statistical significance. Safety profiles were consistent with known profiles of individual agents. Full results will be shared with health authorities and presented at an upcoming scientific meeting.The FIRST trial, an international phase III study led by GINECO, investigated dostarlimab's addition to standard platinum-based chemotherapy and niraparib maintenance in stage III or IV nonmucinous epithelial ovarian cancer. This study aligns with GSK's focus on gynaecological cancers and its commitment to advancing oncology treatments.

GSK announced positive results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first-line advanced ovarian cancer. The trial met its primary endpoint, demonstrating statistically significant progression-free survival (PFS) improvement with dostarlimab added to standard chemotherapy and niraparib maintenance, with or without bevacizumab.The key secondary endpoint of overall survival did not reach statistical significance. Safety profiles were consistent with known profiles of individual agents. Full results will be shared with health authorities and presented at an upcoming scientific meeting.The FIRST trial, an international phase III study led by GINECO, investigated dostarlimab's addition to standard platinum-based chemotherapy and niraparib maintenance in stage III or IV nonmucinous epithelial ovarian cancer. This study aligns with GSK's focus on gynaecological cancers and its commitment to advancing oncology treatments.